- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 02.06. | OncoZenge AB: OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici | 154 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company's licensee, Molteni Farmaceutici.
The company announced on March... ► Artikel lesen | |
| 27.05. | OncoZenge AB: Bulletin From The Annual General Meeting Of OncoZenge | 144 | GlobeNewswire (Europe) | At the annual general meeting ("AGM") of OncoZenge AB (publ) held on 27 May 2026, the following principal resolutions were adopted, in accordance with the proposals submitted by the Board of Directors... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge | 663 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it has received regulatory... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge AB Interim Report January 1 - March 31, 2026 | 155 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the first quarter of 2026. The company reports progress with European authorities expecting regulatory approval... ► Artikel lesen | |
| 22.05. | OncoZenge AB: OncoZenge enters into a loan agreement of SEK 2 million with Linc AB | 126 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") has today entered into an agreement regarding bridge financing of SEK 2 million through a loan provided by one of the Company's largest shareholders... ► Artikel lesen | |
| 19.05. | OncoZenge AB: OncoZenge Provides Regulatory Update on BupiZenge Phase III Trial | 211 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has received written notification from European authorities regarding the ongoing assessment of its Clinical Trial Application... ► Artikel lesen | |
| 28.04. | OncoZenge AB: OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial ('BEAM-Pain') of BupiZenge from European Authorities | 527 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that it has received conditional... ► Artikel lesen | |
| 02.04. | OncoZenge AB: OncoZenge Confirms Submission of Responses to EMA on the BupiZenge Phase III Trial (BZ003) | 113 | GlobeNewswire (Europe) | OncoZenge AB (publ), OncoZenge or "the Company", developing innovative treatments for oral pain management, today announced the complete submission of responses to European authorities' Requests for... ► Artikel lesen | |
| 01.04. | OncoZenge AB: OncoZenge Reports Positive Stability Results for BupiZenge as Key Enabler for the Upcoming Phase III Trial | 121 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the three-month stability study results for its BupiZenge lozenge are within... ► Artikel lesen | |
| 26.02. | OncoZenge AB: OncoZenge AB Year-end Report January 1 - December 31, 2025 | 169 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced its full year report for 2025, a year of significant progress culminating in the submission of the Phase III Clinical Trial Application... ► Artikel lesen | |
| 12.02. | OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical | 281 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor").
The investment... ► Artikel lesen | |
| 02.02. | OncoZenge AB: OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer | 323 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company"), a clinical-stage pharmaceutical company developing innovative treatments for oral pain, today announced the appointment of Dr. Marie-Louise Fjällskog, MD, PhD, as... ► Artikel lesen | |
| 30.01. | OncoZenge AB: OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge Technology Batch, Advancing Toward Clinical Trials | 184 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the one-month stability study results for its BupiZenge lozenge technology... ► Artikel lesen | |
| 22.01. | OncoZenge AB: OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds | 526 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has today entered into an agreement for a bridge financing solution of SEK 5 million, via a convertible note with Linc AB ("Linc") to be repaid upon... ► Artikel lesen | |
| 22.01. | OncoZenge AB receives observation status | 232 | GlobeNewswire | Yesterday, January 21, 2026, OncoZenge AB (the "Company") disclosed a press release with information about uncertainties regarding the payment of the subscription proceeds in a previously announced... ► Artikel lesen | |
| 21.01. | OncoZenge AB: OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact | 295 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company") has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the "Investor") will not be able to pay the subscription proceeds... ► Artikel lesen | |
| 19.12.25 | OncoZenge AB: OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement | 206 | GlobeNewswire (Europe) | The information contained in this press release is not for publication, release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand... ► Artikel lesen | |
| 03.12.25 | OncoZenge AB: OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge for Europe | 173 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company"), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces an amended agreement with... ► Artikel lesen | |
| 17.11.25 | OncoZenge AB: OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge | 235 | GlobeNewswire (Europe) | OncoZenge AB (publ) (Nasdaq First North Growth Market: ONCOZ), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces the addition of... ► Artikel lesen | |
| 30.10.25 | OncoZenge AB: OncoZenge AB Interim Report January 1 - September 30, 2025 | 418 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the third quarter of 2025. The Company reports receipt of investment funds for its European Phase III program... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 42,185 | +0,15 % | Ausbruch dank Novo Nordisk, UnitedHealth und Johnson & Johnson? | Der Chart sieht spannend aus. Dank der zuletzt soliden Performance von Aktien wie UnitedHealth, Novo Nordisk oder Johnson & Johnson könnte der Index "Aktien für immer" bald auf ein neues Jahreshoch... ► Artikel lesen | |
| ASTRAZENECA | 166,10 | +0,39 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem Kursziel von 18000 Pence auf "Buy" belassen. Die anstehenden Phase-III-Daten der Studie gegen ATTR-Kardiomyopathie... ► Artikel lesen | |
| CAMURUS | 49,600 | -0,04 % | Eli Lilly: Es geht Schlag auf Schlag - nächster Deal mit Camurus | Der US-amerikanische Pharma-Riese Eli Lilly bleibt auf Shopping-Tour. Neben zwei Lizenzdeals in Asien konnte das Unternehmen auch eine erweiterte Partnerschaft mit der schwedischen Camurus einfädeln.... ► Artikel lesen | |
| BAYER | 47,000 | 0,00 % | DAX-Check LIVE: Bayer, Infineon, Rheinmetall, Volkswagen Vz., Vonovia im Fokus | Der deutsche Aktienmarkt hat am Mittwoch erneut Verluste hinnehmen müssen. Der DAX schloss 0,6 Prozent tiefer bei 24.740 Punkten und entfernt sich damit weiter von der psychologisch wichtigen Marke... ► Artikel lesen | |
| MERCK KGAA | 145,65 | -0,92 % | EQS-Adhoc: Merck KGaA: Merck vereinbart Akquisition von Bio-Techne Corporation | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Mergers und Acquisitions / Fusion
Merck KGaA: Merck vereinbart Akquisition von Bio-Techne Corporation
25.06.2026 / 11:33 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,390 | 0,00 % | Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? | ||
| JOURNEY MEDICAL | 6,620 | 0,00 % | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,730 | 0,00 % | Canaccord reiterates TriSalus stock Buy rating after KOL event | ||
| ELI LILLY | 1.065,00 | +0,49 % | Eli Lilly: Perfektes Pullback-Setup nach Rekordjagd! | Pharmagigant an charttechnischer Schlüsselmarke! Rückblick Nach einer längeren Konsolidierungsphase bis Ende April startete die Aktie einen dynamischen Aufwärtstrend. Eli Lilly stieg im Juni bis auf... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,770 | -0,47 % | LB Pharmaceuticals stock rating maintained at buy by H.C. Wainwright | ||
| SHUTTLE PHARMACEUTICALS | 3,970 | -1,24 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Purchases Dogecoin Miners and Secures Renewable Energy Data Centre Site | Gaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,550 | +0,49 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| PFIZER | 21,280 | -0,26 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Pfizer von 35 auf 34 US-Dollar gesenkt, aber die Einstufung auf "Buy" belassen. Die Be6A-Lungenkrebsstudie (NSLC) mit Sigvotatug... ► Artikel lesen | |
| KARDIGAN | 23,450 | -0,64 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 35,660 | -0,11 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,018 (+2,83 %) liegt der Kurs bei 0,653 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.